Dosing Considerations for Morbidly Obese Patients with Type 2 Diabetes

Alternative Medication Considerations

• For patients with obesity, GLP-1 receptor agonists, like semaglutide, may be more appropriate first-line or add-on therapy due to their weight loss benefits and lower hypoglycemia risk, as recommended by the Mayo Clinic Proceedings 1, 2
• GLP-1 RAs with proven cardiovascular benefits are preferred for patients with type 2 diabetes and obesity, according to the Mayo Clinic Proceedings 2
• Semaglutide is recommended for weight management in patients with BMI >30 kg/m² or BMI >27 kg/m² with weight-related comorbidities, as suggested by the Mayo Clinic Proceedings and Obesity Reviews 1, 3